Core Insights - TransMedics (TMDX) reported $143.82 million in revenue for Q3 2025, a year-over-year increase of 32.2%, with an EPS of $0.66 compared to $0.12 a year ago, indicating strong growth in financial performance [1] - The revenue fell short of the Zacks Consensus Estimate by 0.76%, while the EPS exceeded the consensus estimate by 78.38% [1] Revenue Breakdown - OCS transplant revenue in the United States totaled $139.01 million, a 32.5% year-over-year increase, but below the average estimate of $141.27 million [4] - OCS transplant revenue from all other countries was $3.63 million, exceeding the average estimate of $3.54 million, representing a 40.5% year-over-year increase [4] - Specific OCS transplant revenues included: - Lung revenue in the U.S. at $3.73 million, below the estimate of $3.96 million [4] - Heart revenue in the U.S. at $27.4 million, below the estimate of $28.6 million [4] - Liver revenue in the U.S. at $107.88 million, slightly below the estimate of $108.54 million [4] - Combined lung net revenue (U.S. & Other countries) at $4.11 million, below the estimate of $4.27 million, with a year-over-year change of 5.2% [4] - Combined heart net revenue (U.S. & Other countries) at $30.59 million, below the estimate of $31.68 million, with a year-over-year change of 13.6% [4] - Combined liver net revenue (U.S. & Other countries) at $107.94 million, below the estimate of $108.63 million, with a year-over-year change of 40.8% [4] Service and Product Revenue - Service revenue was reported at $56.15 million, slightly below the average estimate of $56.76 million, with a year-over-year increase of 30.9% [4] - Net product revenue was reported at $87.68 million, below the average estimate of $89.15 million, with a year-over-year increase of 33.1% [4] Stock Performance - TransMedics shares have returned +15.6% over the past month, outperforming the Zacks S&P 500 composite's +3.8% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]